Jesus Eric Pina-Garza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jesus Eric Pina-Garza has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Edward Tuttle
D Analysis Group Inc. , Menlo Park , CA , USA
3 shared publications- Vicente Villanueva
Hospital Universitario y Politécnico La Fe
3 shared publications Vivienne Shen
E Lundbeck , Deerfield , IL , USA
3 shared publications- Anna Patten
Eisai Ltd., Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK
2 shared publications - Fenella Jane Kirkham
University College London Great Ormond Street Institute of Child Health
2 shared publications Francis Vekeman
A Groupe d'analyse Ltée , Montréal , QC , Canada
2 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (3) , e200616
Addressing Barriers to Transitioning Pediatric Patients With Epilepsy to Adult Health Care in the United States
Adolescents with childhood-onset epilepsy, along with their families, must navigate a complex constellation of uncertainties related to physical, psychological, and social changes as well as medical and possibly legal ramifications as they approach adulthood. Transferring from the familiar pediatric setting to the adult health care system can be a time of concern because of actual and/or perceived differences between the settings (e.g., uncertainty about the patient entering a completely new system, providers focused on adults rather than children, patient behavior in a new environment, and less parental involvement). These concerns can be eased by a focused transition program, with clinicians providing a guiding hand for a smooth transfer into adult health care. Models of transition processes involving epilepsy education, assessment of readiness for transfer, and validation of patient preparedness for self-management, when possible, are available in toolkits and publications. These resources address the need for focused transition care for patients with epilepsy; however, practical suggestions that clearly discuss barriers to transition in the US fee-for-service health care system, and strategies for addressing those barriers, are lacking. In this study, we discuss features of transition programs for patients with epilepsy outside the United States and for patients in the United States with other disease conditions. We then detail the barriers to transition for patients with epilepsy in the United States, compiling them into categories with tables for quick and clear access. Along with the barriers, we provide clinicians treating adolescent patients with epilepsy with resources from which they can select the appropriate features best suited for addressing their institution's needs as well as the needs of patients, including those with complex epilepsies, such as developmental and epileptic encephalopathies.
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (3) , e200616
Open AccessAddressing Barriers to Transitioning Pediatric Patients With Epilepsy to Adult Health Care in the United States
Adolescents with childhood-onset epilepsy, along with their families, must navigate a complex constellation of uncertainties related to physical, psychological, and social changes as well as medical and possibly legal ramifications as they approach adulthood. Transferring from the familiar pediatric setting to the adult health care system can be a time of concern because of actual and/or perceived differences between the settings (e.g., uncertainty about the patient entering a completely new system, providers focused on adults rather than children, patient behavior in a new environment, and less parental involvement). These concerns can be eased by a focused transition program, with clinicians providing a guiding hand for a smooth transfer into adult health care. Models of transition processes involving epilepsy education, assessment of readiness for transfer, and validation of patient preparedness for self-management, when possible, are available in toolkits and publications. These resources address the need for focused transition care for patients with epilepsy; however, practical suggestions that clearly discuss barriers to transition in the US fee-for-service health care system, and strategies for addressing those barriers, are lacking. In this study, we discuss features of transition programs for patients with epilepsy outside the United States and for patients in the United States with other disease conditions. We then detail the barriers to transition for patients with epilepsy in the United States, compiling them into categories with tables for quick and clear access. Along with the barriers, we provide clinicians treating adolescent patients with epilepsy with resources from which they can select the appropriate features best suited for addressing their institution's needs as well as the needs of patients, including those with complex epilepsies, such as developmental and epileptic encephalopathies.
- Open Access
- 27 January 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 176, 110831
Does seizure duration matter? A quantitative and qualitative study on the burden and unmet needs of prolonged seizures in people living with epilepsy and their caregivers
- 27 January 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 176, 110831
Open AccessDoes seizure duration matter? A quantitative and qualitative study on the burden and unmet needs of prolonged seizures in people living with epilepsy and their caregivers
- Open Access
- 30 August 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 159, 109989
Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy
- 30 August 2024
- Published by Elsevier in Epilepsy & Behavior
- Vol. 159, 109989
Open AccessLong-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy
- Open Access
- 30 May 2024
- Published by Wiley in Epileptic Disorders
- Vol. 26 (4) , 484-497
Outpatient management of prolonged seizures and seizure clusters to prevent progression to a higher‐level emergency: Consensus recommendations of an expert working group
Objective: The management of prolonged seizures (PS) and seizure clusters (SC) is impeded by the lack of international, evidence‐based guidance. We aimed to develop expert recommendations regarding consensus definitions of PS, SC, and treatment goals to prevent progression to higher‐level emergencies such as status epilepticus (SE).Methods: An expert working group, comprising 12 epileptologists, neurologists, and pharmacologists from Europe and North America, used a modified Delphi consensus methodology to develop and anonymously vote on statements. Consensus was defined as ≥75% voting “Agree”/”Strongly agree.”Results: All group members strongly agreed that termination of an ongoing seizure in as short a time as possible is the primary goal of rapid and early seizure termination (REST) and that an ideal medication for REST would start to act within 2 min of administration to terminate ongoing seizure activity. Consensus was reached on the terminology defining PS (with proposed thresholds of 5 min for prolonged focal seizures and 2 min for prolonged absence seizures and the convulsive phase of bilateral tonic‐clonic seizures) and SC (an abnormal increase in seizure frequency compared with the individual patient's usual seizure pattern). All group members strongly agreed or agreed that patients who have experienced a PS should be offered a REST medication, and all patients who have experienced a SC should be offered an acute cluster treatment (ACT). Further, when prescribing a REST medication or ACT, a seizure action plan should be agreed upon in consultation with the patient and caregiver.Significance: The expert working group had a high level of agreement on the recommendations for defining and managing PS and SC. These recommendations will complement the existing guidance for the management of acute seizures, with the possibility of treating them earlier to potentially avoid progression to more severe seizures, including SE.
- 30 May 2024
- Published by Wiley in Epileptic Disorders
- Vol. 26 (4) , 484-497
Open AccessOutpatient management of prolonged seizures and seizure clusters to prevent progression to a higher‐level emergency: Consensus recommendations of an expert working group
Objective: The management of prolonged seizures (PS) and seizure clusters (SC) is impeded by the lack of international, evidence‐based guidance. We aimed to develop expert recommendations regarding consensus definitions of PS, SC, and treatment goals to prevent progression to higher‐level emergencies such as status epilepticus (SE).Methods: An expert working group, comprising 12 epileptologists, neurologists, and pharmacologists from Europe and North America, used a modified Delphi consensus methodology to develop and anonymously vote on statements. Consensus was defined as ≥75% voting “Agree”/”Strongly agree.”Results: All group members strongly agreed that termination of an ongoing seizure in as short a time as possible is the primary goal of rapid and early seizure termination (REST) and that an ideal medication for REST would start to act within 2 min of administration to terminate ongoing seizure activity. Consensus was reached on the terminology defining PS (with proposed thresholds of 5 min for prolonged focal seizures and 2 min for prolonged absence seizures and the convulsive phase of bilateral tonic‐clonic seizures) and SC (an abnormal increase in seizure frequency compared with the individual patient's usual seizure pattern). All group members strongly agreed or agreed that patients who have experienced a PS should be offered a REST medication, and all patients who have experienced a SC should be offered an acute cluster treatment (ACT). Further, when prescribing a REST medication or ACT, a seizure action plan should be agreed upon in consultation with the patient and caregiver.Significance: The expert working group had a high level of agreement on the recommendations for defining and managing PS and SC. These recommendations will complement the existing guidance for the management of acute seizures, with the possibility of treating them earlier to potentially avoid progression to more severe seizures, including SE.
- Open Access
- 25 May 2023
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 110, 42-57
Proposed anti-seizure medication combinations with rufinamide in the treatment of Lennox-Gastaut syndrome: Narrative review and expert opinion
- 25 May 2023
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 110, 42-57
Open AccessProposed anti-seizure medication combinations with rufinamide in the treatment of Lennox-Gastaut syndrome: Narrative review and expert opinion
- Open Access
- 16 September 2022
- Published by Elsevier in Epilepsy & Behavior
- Vol. 135, 108901
Assessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies
- 16 September 2022
- Published by Elsevier in Epilepsy & Behavior
- Vol. 135, 108901
Open AccessAssessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies
- Open Access
- 1 November 2020
- Published by Elsevier in Epilepsy & Behavior
- Vol. 112, 107458
Long-term safety and tolerability of adjunctive eslicarbazepine acetate in children with focal seizures
- 1 November 2020
- Published by Elsevier in Epilepsy & Behavior
- Vol. 112, 107458
Open AccessLong-term safety and tolerability of adjunctive eslicarbazepine acetate in children with focal seizures
- 14 April 2020
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (15_supplem)
Long-term Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4–17 years) with Focal Seizures (263)
- 14 April 2020
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (15_supplem)
Long-term Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4–17 years) with Focal Seizures (263)
- Open Access
- 1 March 2020
- Published by Elsevier in Epilepsy & Behavior
- Vol. 104, 106876
Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies
- 1 March 2020
- Published by Elsevier in Epilepsy & Behavior
- Vol. 104, 106876
Open AccessEfficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies
- 29 April 2019
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 35 (8) , 1415-1420
Development of a classifier to identify patients with probable Lennox–Gastaut syndrome in health insurance claims databases via random forest methodology
Objective: Describe the development of a claims-based classifier utilizing machine learning to identify patients with probable Lennox–Gastaut syndrome (LGS) from 6 state Medicaid programs. Methods: Patients were included if they had ≥2 medical claims ≥30 days apart for specified or unspecified epilepsy, excluding those with ≥1 claim for petit mal status. The LGS classifier utilized a random forest algorithm, a compilation of thousands of binary decision trees in which machine-generated predictor variables split the data set into branches that predict the presence or absence of LGS. To construct the splitting rules, the importance of each candidate variable was determined by calculating mean decrease in Gini impurity. Training and testing were performed on 2 data sets (30% and 70%) using a “true” LGS and non-LGS patient population. Performance was compared with logistic regression and single tree methodology. Results: Using a 60% probability threshold, which yielded the highest sensitivity (97.3%) and specificity (95.6%), the classifier identified approximately 4% of patients with epilepsy as probable LGS. The most important input variables included number of distinct antiepileptic drugs received, epilepsy-related outpatient/inpatient visits, electroencephalogram procedures, and claims for delayed development. The random forest methodology outperformed logistic regression and single tree methodology. Most of the important LGS predictor characteristics identified by the classifier were statistically significantly associated with LGS status (P < 0.05). Conclusions: The claims-based LGS classifier showed high sensitivity and specificity, outperformed single tree and logistic regression methodologies, and identified a prevalence of probable LGS that was similar to previously published estimates.
- 29 April 2019
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 35 (8) , 1415-1420
Development of a classifier to identify patients with probable Lennox–Gastaut syndrome in health insurance claims databases via random forest methodology
Objective: Describe the development of a claims-based classifier utilizing machine learning to identify patients with probable Lennox–Gastaut syndrome (LGS) from 6 state Medicaid programs. Methods: Patients were included if they had ≥2 medical claims ≥30 days apart for specified or unspecified epilepsy, excluding those with ≥1 claim for petit mal status. The LGS classifier utilized a random forest algorithm, a compilation of thousands of binary decision trees in which machine-generated predictor variables split the data set into branches that predict the presence or absence of LGS. To construct the splitting rules, the importance of each candidate variable was determined by calculating mean decrease in Gini impurity. Training and testing were performed on 2 data sets (30% and 70%) using a “true” LGS and non-LGS patient population. Performance was compared with logistic regression and single tree methodology. Results: Using a 60% probability threshold, which yielded the highest sensitivity (97.3%) and specificity (95.6%), the classifier identified approximately 4% of patients with epilepsy as probable LGS. The most important input variables included number of distinct antiepileptic drugs received, epilepsy-related outpatient/inpatient visits, electroencephalogram procedures, and claims for delayed development. The random forest methodology outperformed logistic regression and single tree methodology. Most of the important LGS predictor characteristics identified by the classifier were statistically significantly associated with LGS status (P < 0.05). Conclusions: The claims-based LGS classifier showed high sensitivity and specificity, outperformed single tree and logistic regression methodologies, and identified a prevalence of probable LGS that was similar to previously published estimates.